Key Takeaways
- • Emma Davies, former co-CEO of Octopus Ventures, appointed Chief Investment Officer of Guy's and St Thomas' Foundation, effective May 2023, replacing Ethan Hall who held the position since 2021.
- • Foundation's £1bn endowment grew from £693m to £931m between 2017 and 2022, with over £130m deployed for charitable spending during the period, including grants to sister organization Guy's and St Thomas' NHS Foundation Trust.
- • Portfolio generated 12.8% return in 2021/22, underperforming the 16.4% benchmark for that year but outperforming across the five-year period, demonstrating mixed near-term performance against indices.
- • Davies will oversee a dual-mandate investment strategy combining financial returns with health impact generation, including stewardship of the foundation's recently announced £100m impact investment portfolio launched in 2022.
- • Davies brings diversified institutional capital experience spanning venture capital (healthcare and environmental tech focus), philanthropic infrastructure (Wellcome), and social enterprise financing (Big Society Capital founding CIO role).
Summary
Emma Davies has been appointed Chief Investment Officer of Guy's and St Thomas' Foundation, one of the United Kingdom's largest health-focused charitable endowments. The appointment becomes effective in May 2023 and represents a leadership transition in the foundation's investment function, succeeding Ethan Hall who served in the role since 2021. Davies previously co-led Octopus Ventures, a venture capital firm specializing in healthcare and environmental technology investments, and brings extensive experience in capital deployment across both commercial and philanthropic sectors.
The foundation's endowment has demonstrated significant growth momentum. According to the latest published accounts, the endowment expanded from £693m to £931m between 2017 and 2022—a 34% increase over the five-year period. During this timeframe, the foundation deployed over £130m in charitable spending, including substantial distributions to its sister entity, Guy's and St Thomas' NHS Foundation Trust. This dual-entity structure underscores the foundation's role as both an independent charity and a capital source for a major National Health Service provider.
Investment performance has been nuanced. The endowment portfolio delivered a 12.8% return in the 2021/22 financial year, falling short of the 16.4% benchmark for that period. However, across the broader five-year interval, the portfolio has outperformed its comparative benchmark, indicating resilient long-term performance despite recent underperformance relative to market indices. This context is relevant to Davies' mandate, which carries measurable performance expectations alongside mission-driven objectives.
Davies' appointment reflects the foundation's strategic emphasis on impact-aligned investing. The foundation has committed to a £100m impact investment portfolio announced in 2022, designed to generate both financial returns and measurable health outcomes. In a statement, Davies characterized this dual mandate as "ambitious and exciting," noting that it positions foundations and mainstream institutional investors as leaders in demonstrating how capital can be deployed to "build a healthier society." Her appointment signals the foundation's intent to advance sophisticated impact measurement and management alongside traditional endowment stewardship responsibilities.
The foundation's endowment has demonstrated significant growth momentum. According to the latest published accounts, the endowment expanded from £693m to £931m between 2017 and 2022—a 34% increase over the five-year period. During this timeframe, the foundation deployed over £130m in charitable spending, including substantial distributions to its sister entity, Guy's and St Thomas' NHS Foundation Trust. This dual-entity structure underscores the foundation's role as both an independent charity and a capital source for a major National Health Service provider.
Investment performance has been nuanced. The endowment portfolio delivered a 12.8% return in the 2021/22 financial year, falling short of the 16.4% benchmark for that period. However, across the broader five-year interval, the portfolio has outperformed its comparative benchmark, indicating resilient long-term performance despite recent underperformance relative to market indices. This context is relevant to Davies' mandate, which carries measurable performance expectations alongside mission-driven objectives.
Davies' appointment reflects the foundation's strategic emphasis on impact-aligned investing. The foundation has committed to a £100m impact investment portfolio announced in 2022, designed to generate both financial returns and measurable health outcomes. In a statement, Davies characterized this dual mandate as "ambitious and exciting," noting that it positions foundations and mainstream institutional investors as leaders in demonstrating how capital can be deployed to "build a healthier society." Her appointment signals the foundation's intent to advance sophisticated impact measurement and management alongside traditional endowment stewardship responsibilities.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.